Otolaryngology Head and Neck Surgery, Zhongda Hospital Southeast University, Nanjing 210009, Jiangsu, China.
Hyperbaric Oxygen Department, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, Shandong, China.
Noise Health. 2024;26(122):370-375. doi: 10.4103/nah.nah_60_24. Epub 2024 Sep 30.
To evaluate the clinical effect of retroaural injection of methylprednisolone sodium succinate combined with hyperbaric oxygen (HBO) on the treatment of noise-induced hearing loss.
Case data of 220 patients with hearing loss treated at the Zhongda Hospital Southeast University from January 1, 2019 to August 1, 2023 were obtained. As per the treatment plan, the recruited patients were divided into two cohorts: 158 cases in the combined-treatment group (retroaural injection of methylprednisolone sodium succinate combined with HBO) and 62 cases in the single-hormone group (retroaural injection of methylprednisolone sodium succinate). Comparison of the clinical efficacies and postoperative complication rates of the two groups was performed after treatment. MS-Excel was used to build a database for all data, and SPSS26.0 was utilized in the statistical analysis of recorded data.
For patients with low-frequency, high-frequency, and flat descending type, the combined-treatment group showed significantly higher clinical effective rate than the single-hormone group (P < 0.05). For patients with disease duration ≤7 days, the combined-treatment group attained a significantly higher clinical effective rate was than the single-hormone group (P < 0.05). The safety of patients in both groups was evaluated mainly through their adverse reactions. The total incidence of adverse reactions in the single-hormone group reached 9.68%, and that in the combined-treatment group was 8.23%. The two groups revealed no significant difference in terms of incidence of adverse reactions (P > 0.05).
HBO combined with retroaural injection of methylprednisolone sodium succinate has good clinical efficacy and safety in the treatment of hearing loss.
评估耳后注射甲泼尼龙琥珀酸钠联合高压氧（HBO）治疗噪声性听力损失的临床效果。
选取 2019 年 1 月 1 日至 2023 年 8 月 1 日东南大学中大医院收治的听力损失患者 220 例，根据治疗方案将患者分为联合治疗组（耳后注射甲泼尼龙琥珀酸钠联合 HBO）和单激素组（耳后注射甲泼尼龙琥珀酸钠），每组各 158 例和 62 例。治疗后比较两组的临床疗效和术后并发症发生率。采用 MS-Excel 建立数据库录入所有数据，采用 SPSS26.0 进行记录数据的统计学分析。
低频、高频、平坦下降型患者，联合治疗组临床有效率显著高于单激素组（P＜0.05）；病程≤7d 的患者，联合治疗组临床有效率显著高于单激素组（P＜0.05）。两组患者安全性主要通过不良反应评估，单激素组不良反应总发生率为 9.68%，联合治疗组为 8.23%，两组不良反应发生率差异无统计学意义（P＞0.05）。
HBO 联合耳后注射甲泼尼龙琥珀酸钠治疗听力损失具有良好的临床疗效和安全性。
